GlaxoSmithKline, plc (GSK) - Bear of the Day

By Zacks.com,  August 07, 2012, 01:00:01 AM EDT

GlaxoSmithKline, plc's ( GSK ) second quarter earnings of $0.79 per ADS were below the Zacks Consensus Estimate of $0.84. Earnings fell 2.5% year over year. Revenues fell 7.3% y/y to $10.2 billion, missing the Zacks Consensus Estimate of $10.4 billion.

Glaxo expects 2012 revenues to remain flat y/y (at CER). Earlier, Glaxo was expecting revenues to grow from 2011 levels. Guidance was lowered due to EU pricing pressure. A major part of Glaxo's revenues will be exposed to generic competition as multiple drugs are scheduled to lose exclusivity in the next few years. We expect the company's top line as well as gross margins to remain under pressure in the coming quarters.

In addition to generic competition, US health care reform and EU pricing pressure will continue to affect sales. Thus, we maintain our Underperform recommendation on Glaxo, which carries a Zacks #4 Rank (short-term Sell rating).
 
GLAXOSMITHKLINE (GSK): Free Stock Analysis Report
 
To read this article on Zacks.com click here.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.


This article appears in: Investing, Stocks

Referenced Stocks: GSK



Latest News Video

Afghan Parliament Blocks Landmark Women's Rights Bill
Afghan Parliament Blocks Landmark W...
Thai Anti-Government Party Marks Anniversary of Bloody Crackdown
Thai Anti-Government Party Marks An...


Sign-in
Existing NASDAQ.com member? Log in here.

By signing into to the site using any of the third-party services above, you agree to NASDAQ.com's Terms of Use.

From Our Trusted News Source





Most Active by Volume:

Company Last Sale Change Net / %
BAC $ 13.43 0.07  0.52%
CSCO $ 24.24 0.35  1.48%
MSFT $ 34.87 0.79  2.32%
F $ 15.08 0.44  3.01%
ARUN $ 13.10 4.51  25.61%
SIRI $ 3.50 0.05  1.45%
GE $ 23.46 0.19  0.82%
S $ 7.32 0.04  0.55%